CKR-7 Inhibitors
CKR-7, a chemokine receptor, is subject to modulation by a distinct class of compounds known as CKR-7 inhibitors. These inhibitors exert their effects through various mechanisms, collectively leading to the modulation or inhibition of CKR-7. SB 203580 indirectly influences CKR-7 by targeting p38 MAP kinase, a kinase implicated in CKR-7 regulation. LY294002, a selective PI3K inhibitor, modulates CKR-7 through the PI3K/Akt signaling pathway. PD98059 inhibits MEK1, impacting the MAPK/ERK pathway associated with CKR-7 signaling. SP600125, a JNK inhibitor, indirectly influences CKR-7 by targeting the JNK signaling pathway.
Wortmannin inhibits PI3K, leading to indirect modulation of CKR-7 through the PI3K pathway. U0126 inhibits MEK1/2, impacting the MAPK/ERK pathway linked to CKR-7 regulation. LY303511, a PI3K inhibitor, modulates CKR-7 through the PI3K/Akt pathway. SP203580 targets p38 MAP kinase, indirectly influencing CKR-7 regulation. JNK inhibitor II specifically inhibits JNK, intersecting with CKR-7-mediated cellular processes. ZSTK474, a pan-PI3K inhibitor, modulates CKR-7 through the PI3K pathway. PD184352 inhibits MEK1/2, impacting the MAPK/ERK pathway associated with CKR-7 signaling. AS601245 selectively inhibits p38 MAP kinase, indirectly influencing CKR-7 regulation. Collectively, these compounds represent a diverse array of agents capable of specifically modulating CKR-7 through targeted inhibition of key signaling pathways involved in CKR-7-mediated cellular processes.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB 203580 is a potent inhibitor of p38 MAP kinase, a kinase involved in the MAPK signaling pathway. By targeting p38, SB 203580 indirectly modulates CKR-7, as p38 MAP kinase is known to regulate CKR-7 expression and activity in certain cellular contexts. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is a selective inhibitor of phosphoinositide 3-kinase (PI3K), a key regulator of the PI3K/Akt signaling pathway. Inhibition of PI3K by LY294002 indirectly influences CKR-7, as the PI3K/Akt pathway is implicated in CKR-7-mediated cellular processes. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD98059 inhibits MEK1, a component of the MAPK/ERK signaling pathway. By targeting MEK1, PD98059 indirectly modulates CKR-7, as the MAPK/ERK pathway is associated with CKR-7 signaling and regulation. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is a potent inhibitor of c-Jun N-terminal kinase (JNK), a kinase involved in the JNK signaling pathway. Inhibition of JNK by SP600125 indirectly influences CKR-7, as the JNK pathway intersects with CKR-7-mediated cellular processes. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin is a fungal metabolite and a potent inhibitor of phosphoinositide 3-kinase (PI3K). Inhibition of PI3K by Wortmannin indirectly modulates CKR-7, as the PI3K pathway is implicated in CKR-7-mediated cellular processes. | ||||||
LY 303511 | 154447-38-8 | sc-202215 sc-202215A | 1 mg 5 mg | $67.00 $278.00 | 3 | |
LY303511 is a structural analog of LY294002 and acts as a PI3K inhibitor. Inhibition of PI3K by LY303511 indirectly influences CKR-7, as the PI3K/Akt pathway is implicated in CKR-7-mediated cellular processes. | ||||||
ZSTK 474 | 475110-96-4 | sc-475495 | 5 mg | $75.00 | ||
ZSTK474 is a pan-PI3K inhibitor, targeting multiple isoforms of phosphoinositide 3-kinase (PI3K). Inhibition of PI3K by ZSTK474 indirectly modulates CKR-7, as the PI3K pathway is implicated in CKR-7-mediated cellular processes. | ||||||
PD 184,352 | 212631-79-3 | sc-202759 sc-202759A | 1 mg 5 mg | $40.00 $260.00 | 34 | |
PD184352 inhibits MEK1/2, key components of the MAPK/ERK signaling pathway. By targeting MEK1/2, PD184352 indirectly modulates CKR-7, as the MAPK/ERK pathway is involved in CKR-7 signaling and regulation. | ||||||
JNK Inhibitor V | 345987-15-7 | sc-202672A sc-202672 | 1 mg 5 mg | $60.00 $169.00 | 3 | |
JNK Inhibitor V (AS601245) is a selective p38 MAP kinase inhibitor. By inhibiting p38 MAP kinase, AS601245 indirectly modulates CKR-7, as p38 MAP kinase is known to regulate CKR-7 expression and activity in certain cellular contexts. | ||||||